Results from 327 women demonstrated: Significant increases in satisfying sexual events compared to placebo at 1.25 mg and 1.75 mg doses Improved Female Sexual Function Index total scores (mean improvement of 3.6 points vs 1.9 for placebo) Reduced sexual distress as measured by Female Sexual Distress Scale scores Dose-dependent response with optimal effects at 1.75 mg Two Phase 3 trials (RECONNECT studies) enrolled over 1,200 premenopausal women with acquired, generalized HSDD and confirmed efficacy at the 1.75 mg dose administered subcutaneously at least 45 minutes before anticipated sexual activity
2025, Apr;47(2):224561 Kankaya S, Yavuz F, Tari A, Aygun AB, Gunes EG, Bektan Kanat B, et al
Learn how your body responds, stabilize your dose, and establish a baseline before introducing AOD-9604
The patches do not stay on
Prolactin receptor expression during adipocyte differentiation of bone marrow stroma
Compared with LIXI, LIR is more effective in improving blood glucose and reducing weight, and both treatments are well tolerated (75, 77, 78)
